Neostig (Neostigmine Methylsulfate)

Neostigmine methylsulfate reversibly blocks acetylcholinesterase, the enzyme that breaks down acetylcholine. By inhibiting this enzyme, the drug raises acetylcholine levels at nicotinic receptors in skeletal muscle and at muscarinic receptors in the gastrointestinal tract, enhancing neuromuscular transmission and promoting intestinal motility.

The dosage of Neostig is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and response to therapy. Healthcare professionals calculate the appropriate amount and route (intravenous, intramuscular, or subcutaneous) according to established clinical guidelines.

Safety data for Neostig in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To request Neostig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Neostig belongs to the cholinesterase inhibitor class, whereas alternative reversal agents such as sugammadex act by encapsulating specific neuromuscular blockers. Neostig requires co‑administration of an anticholinergic to offset muscarinic side effects, while sugammadex does not. Choice of agent depends on the blocking drug used, patient comorbidities, and institutional protocols.

Neostig should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to local regulations.

Neostig is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. The route and rate of injection are determined by the treating clinician, who may also use an anticholinergic agent (e.g., glycopyrrolate) to mitigate muscarinic side effects.

Serious adverse events include bronchospasm, cholinergic crisis (excessive muscarinic stimulation), severe hypotension, and cardiac arrhythmias such as bradyarrhythmias. Prompt recognition and supportive measures, including airway management and anticholinergic therapy, are essential if these reactions occur.

Neostig is contraindicated in patients with known hypersensitivity to neostigmine or any component of the formulation, in those with severe asthma or active bronchospasm, and in individuals with uncontrolled bradycardia or recent myocardial infarction unless benefits outweigh risks and close monitoring is ensured.